Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.20%
SPX
-0.64%
IXIC
-1.15%
FTSE
+0.10%
N225
-1.24%
AXJO
-0.51%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

COO is now overvalued and could go down -23%

Feb 08, 2025, 1:00 PM
-9.17%
What does COO do
The Cooper Companies, based in San Ramon, California, employs 15,000 and operates through CooperVision, focused on contact lenses, and CooperSurgical, specializing in fertility and women's health solutions.
Based on our analysis, Cooper Companies has received a fairly valued rating of 2 out of 5 stars from Cashu. Several key financial ratios highlight areas of concern when comparing Cooper Companies to its sector peers. The Price-to-Earnings (PE) ratio for Cooper Companies stands at 48.48, significantly higher than the sector average of 14.76. A high PE ratio may suggest that the stock is overvalued, as investors are paying more for each dollar of earnings compared to others in the industry. This could indicate that growth expectations are not being met, which may lead to price corrections in the future. Additionally, Cooper Companies has a Return on Equity (ROE) of 4.85, compared to a sector benchmark of -74.88. While a positive ROE suggests the company is generating profit from shareholders' equity, it is relatively low and indicates that the company may not be utilizing its equity efficiently compared to the sector. Furthermore, the company currently offers a Dividend Yield of 0.00, in contrast to the sector's average of 0.24. This absence of dividends may deter income-focused investors, as it reflects a lack of cash returns to shareholders. In summary, while Cooper Companies demonstrates strong performance in certain areas, its elevated PE ratio, low ROE, and absence of dividend payments suggest that it may be fairly valued rather than a compelling investment opportunity at this time. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!